260 ladies identified for the study. Small trial. Limited ability to state conclusively on topic.
Equipoise is there - the clinical question makes sense.
Retrospective analysis done on the individuals identified over 1997 to 2007 via a database at NW Uni.
IV dexamethasone between 4-10mg given - one off.
Only an adequately powered randomized trial will confirm or refute an effect of perioperative dexamethasone on recurrence of ovarian cancer.
In summary, considerable previous work indicates that dexamethasone is effective for prevention of postoperative nausea, vomiting, and pain. We could not nd evidence for an association between perioperative administration of dexamethasone and ovarian cancer recurrence. Our results thus do not support avoiding low-dose perioperative dexa- methasone in women having primary cytoreductive surgery for ovarian cancer.
USE OF THIS WEBSITE IS SUBJECT TO AGREEING TO THIS DISCLAIMER